Browsing Tag
Hansa Biopharma
3 posts
How Hansa Biopharma’s imlifidase could redefine access for hardest-to-match transplant candidates
Hansa Biopharma seeks FDA approval for imlifidase to expand transplant eligibility in high-risk ESRD patients. See what this filing means for U.S. access.
Hansa Biopharma targets Q3 2026 approval for imlifidase with Priority Review request
Hansa Biopharma submits imlifidase BLA to the FDA, aiming to transform access to kidney transplants for highly sensitized patients. Read more on what’s next.
Imlifidase clears pivotal US Phase 3 trial with strong kidney transplant results as Hansa Biopharma eyes FDA filing
Hansa Biopharma’s Imlifidase meets its Phase 3 trial endpoint in US kidney transplantation, setting up FDA filing and reshaping biotech investor sentiment.